1. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies.
- Author
-
Saengboon, Supawee, Ciurea, Stefan, Popat, Uday, Ramdial, Jeremy, Bashir, Qaiser, Alousi, Amin, Chen, Julianne, Rondon, Gabriela, Olson, Amanda, Im, Jin, Hosing, Chitra, Shpall, Elizabeth, Champlin, Richard, and Srour, Samer
- Subjects
Humans ,Middle Aged ,Adult ,Hematologic Neoplasms ,Male ,Female ,Adolescent ,Aged ,Hematopoietic Stem Cell Transplantation ,Young Adult ,Graft vs Host Disease ,Transplantation ,Haploidentical ,Retrospective Studies ,Treatment Outcome ,Cyclophosphamide - Abstract
The introduction of posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis lead to significant improvements in haploidentical stem cell transplantation (haplo-SCT) outcomes over the past decade. We retrospectively assessed long-term outcomes of patients who had their first haplo-SCT between February 2009 and March 2019. Long-term survivors were defined as patients who were alive and disease-free at 2 years after transplant. Three hundred thirty-five patients with a median age of 48 years (range, 18-72) were identified. Of these, 142 patients were disease-free and alive at 2 years after transplant. The 4-year progression-free survival (PFS) and overall survival (OS) for all study patients were 42% and 47%, respectively. With a median follow-up of 52 months for the long-term survivor group, the 4-year PFS and OS were 94% and 96%, respectively. The 4-year cumulative incidence of relapse and non-relapse mortality (NRM) were 2.9% and 3.3%, respectively. Age ≥55 years was the only predictive factor in multivariate analysis for inferior PFS (hazard ratio [HR], 3.41; 95% confidence interval [CI], 1.21-9.60; P = .020) and OS (HR, 3.31; 95% CI, 1.08-10.18; P = .037). Thirteen patients (9%) died in the long-term survivor group, only 2 of whom died of relapsed disease. Secondary primary malignancy was the most frequent cause of NRM (n = 4), followed by infection (n = 2). For haplo-SCT with PTCy-based GVHD prophylaxis, our findings suggest an excellent long-term survival for patients who were disease-free and alive at 2 years after transplant. Late relapses were rare, and age was the only predictive factor for long-term outcomes.
- Published
- 2024